Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
13:53 MIN
  • CIDP
  • GBS
  • MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

DOWNLOAD PDF
CIDP Assessment Tools: Grip Strength
Jeffrey A. Allen, MD
University of Minnesota
01:52 MIN
  • CIDP
Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
5:24 MIN
  • CIDP

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

DOWNLOAD PDF
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN
  • CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF
NOW PLAYING
13:53
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

NOW PLAYING
01:52
CIDP Assessment Tools: Grip Strength
Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP
NOW PLAYING
5:24
Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

NOW PLAYING
14:01
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

Our Experts on CIDP

Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
Vera Bril, BSc, FRCPC, MD
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
  • CIDP
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
  • CIDP
  • GBS
Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
  • CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

  • CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
PDF | 0.98 MB
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
PDF | 2.2 MB
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
PDF | 2.35 MB
Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 421 KB
Back to Top